Our Focus

Ascletis focus on breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody - ASC22 and Pegasys® as cornerstone drugs. 



HBV Clinical Cure: ASC22 mechanism

image.png


Prolonged activation of T cells leads to high expression of PD-1. By blocking the connection between PD-1 and PDL-1 through PD-1 antibodies or PD-L1 antibodies, T-cells can remain activated and exert immune functions, ultimately leading to clinical cure.

ASC22介绍英文.jpg




In the area of chronic hepatitis C, Ascletis has twoall-oral regimen, among which ASCLEVIR®/GANOVO®regimen has been approved for marketing for marketing in China by National Medical Products Administration (NMPA).


丙肝靶点图.jpg




Publications


Title

Journal

Type

Date


First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients 


 Medicine

Paper

2020


Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China 


Journal of Clinical and Translational Hepatology

Paper

2019


Efficacy and  safety of 12-week interferon-based danoprevir regimen in patients with  genotype 1 chronic hepatitis C


Journal of Clinical and Translational Hepatology

Paper

2019


Twelve-week  Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non- cirrhotic  HCV genotype 1 patients: A phase 2 study


Journal of Gastroenterology and Hepatology

Paper

2018


Ritonavir-boosted  danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic  hepatitis C patients with or without cirrhosis 


Journal of Gastroenterology and Hepatology

Paper

2016


DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4


Liver International

Paper

2015


All-oral, 12-week  ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100%  svr12 in treatment-naive noncirrhotic hcv genotype 1 patients with  resistance-associated substitutions of a phase 2/3 clinical trial in China


Journal of Hepatology

Poster

2019


12 week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin achieves 99% SVR12 in treatment-naı ¨ve non- cirrhotic HCV GT1 patients: Subanalysis of phase 2/3 clinical trial in China


Hepatol Int

Poster

2019


The Effcacy and  Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and  Ribavirin in Treatment-Naïve Non-Cirrhotic HCV Genotype 1 Patients : Results  from a Phase 2/3 Clinical Trial in China


Hepatology

Poster

2018


MAKALU:  Twelve-week of treatment with Ritonavir-boosted Danoprevir Pluzs Peginterferon  and Ribavirin produces 96% SVR12 in HCV Genotype 1-Infected Non-Cirrhotic  Chinese Patients


Hepatol Int

Poster

2017